Oncimmune to publish full year results on 30th October 2020

Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, will be announcing its full year results for the year ended 31 May 2020 on Friday, 30 October 2020.

Adam Hill, Chief Executive Officer, together with Matthew Hall, Chief Financial Officer, will host a presentation and conference call for analysts at 11:30am GMT on the day of the results.

For conference call details please contact Alexander Davis of FTI Consulting at Alexander.Davis@fticonsulting.com or 020 3727 1000.

The management team will also host on Investor Meet Company a live presentation of the results on Friday, 30 October at 15:00 GMT.

•     The online presentation will be open to all existing shareholders and potential new investors.

•     Questions can be submitted before the event via your Investor Meet Company dashboard or at any time during the live presentation via the “Ask a Question” function. Responses to the Q&A will be published at the earliest opportunity on the Investor Meet Company platform.

•     Investor feedback can also be submitted directly to management immediately following the event.

Access to Investor Meet Company is free and interested parties can register to attend the presentation via the following link: https://www.investormeetcompany.com/essensys-plc/register-investor 

Attendees who have already registered on the Investor Meet Company platform to meet the Company will automatically receive an invitation to the presentation.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Share on facebook
    Share on twitter
    Share on linkedin

    More articles like this

    Oncimmune FY21 revenues in line with market expectations

    Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has provided a trading update for the 12 months ended 31 May 2021. The Company expects to announce its FY21 results in late September 2021. FY21 revenues in line

    Oncimmune acquires China rights to EarlyCDT product portfolio

    Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced that it has successfully agreed to acquire the intellectual property and distribution rights for the EarlyCDT® technology in the People’s Republic of China and Hong Kong from Genostics Company Limited,